JULIE BOOM to Infant
This is a "connection" page, showing publications JULIE BOOM has written about Infant.
Connection Strength
0.911
-
The effect of screening for vaccine hesitancy on the subsequent development of hesitancy: a randomized controlled trial, Houston, TX. Hum Vaccin Immunother. 2021 07 03; 17(7):1994-2000.
Score: 0.065
-
Arboviral Surveillance among Pediatric Patients with Acute Febrile Illness in Houston, Texas. Am J Trop Med Hyg. 2018 08; 99(2):413-416.
Score: 0.054
-
Understanding the Financial Implications of Immunization Reminder/Recall in a Multipractice Pediatric Group. Acad Pediatr. 2017 04; 17(3):323-329.
Score: 0.047
-
Variation in rotavirus vaccine coverage by provider location and subsequent disease burden. Pediatrics. 2015 Feb; 135(2):e432-9.
Score: 0.043
-
The Texas Children's Hospital immunization forecaster: conceptualization to implementation. Am J Public Health. 2014 Dec; 104(12):e65-71.
Score: 0.042
-
Symptomatic infection and detection of vaccine and vaccine-reassortant rotavirus strains in 5 children: a case series. J Infect Dis. 2012 Oct; 206(8):1275-9.
Score: 0.036
-
Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J. 2010 Dec; 29(12):1133-5.
Score: 0.032
-
Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics. 2010 Feb; 125(2):e199-207.
Score: 0.030
-
Utilizing peer academic detailing to improve childhood immunization coverage levels. Health Promot Pract. 2010 May; 11(3):377-86.
Score: 0.028
-
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
Score: 0.020
-
Respiratory Syncytial Virus-Associated Hospitalizations Among Children <5 Years Old: 2016 to 2020. Pediatrics. 2024 Mar 01; 153(3).
Score: 0.020
-
Maternal Vaccine Effectiveness Against Influenza-Associated Hospitalizations and Emergency Department Visits in Infants. JAMA Pediatr. 2024 Feb 01; 178(2):176-184.
Score: 0.020
-
Respiratory viral detection in the plasma and cerebrospinal fluid (CSF) of young febrile infants. Influenza Other Respir Viruses. 2024 Feb; 18(2):e13250.
Score: 0.020
-
SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023. MMWR Morb Mortal Wkly Rep. 2023 Dec 01; 72(48):1300-1306.
Score: 0.020
-
Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19-Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance - 20 States, March 9, 2022-May 31, 2023. MMWR Morb Mortal Wkly Rep. 2023 Sep 29; 72(39):1057-1064.
Score: 0.020
-
Clinical Presentation and Severity of Adenovirus Detection Alone vs Adenovirus Co-detection With Other Respiratory Viruses in US Children With Acute Respiratory Illness from 2016 to 2018. J Pediatric Infect Dis Soc. 2022 Oct 25; 11(10):430-439.
Score: 0.018
-
Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses - New Vaccine Surveillance Network, United States, 2016-2021. MMWR Morb Mortal Wkly Rep. 2022 Oct 07; 71(40):1253-1259.
Score: 0.018
-
Factors Associated With Severe Illness in Patients Aged <21 Years Hospitalized for COVID-19. Hosp Pediatr. 2022 09 01; 12(9):760-783.
Score: 0.018
-
Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants. N Engl J Med. 2022 07 14; 387(2):109-119.
Score: 0.018
-
Understanding Variation in Rotavirus Vaccine Effectiveness Estimates in the United States: The Role of Rotavirus Activity and Diagnostic Misclassification. Epidemiology. 2022 09 01; 33(5):660-668.
Score: 0.018
-
Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):264-270.
Score: 0.018
-
Clinical Influenza Testing Practices in Hospitalized Children at United States Medical Centers, 2015-2018. J Pediatric Infect Dis Soc. 2022 Jan 27; 11(1):5-8.
Score: 0.018
-
Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 - Six Hospitals, United States, July-August 2021. MMWR Morb Mortal Wkly Rep. 2021 12 31; 70(5152):1766-1772.
Score: 0.017
-
Enterovirus D68-Associated Acute Respiratory Illness - New Vaccine Surveillance Network, United States, July-November 2018-2020. MMWR Morb Mortal Wkly Rep. 2021 Nov 26; 70(47):1623-1628.
Score: 0.017
-
Rotavirus Genotype Trends and Gastrointestinal Pathogen Detection in the United States, 2014-2016: Results From the New Vaccine Surveillance Network. J Infect Dis. 2021 11 16; 224(9):1539-1549.
Score: 0.017
-
Effect of Vaccination on Preventing Influenza-Associated Hospitalizations Among Children During a Severe Season Associated With B/Victoria Viruses, 2019-2020. Clin Infect Dis. 2021 08 16; 73(4):e947-e954.
Score: 0.017
-
Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study. Pediatrics. 2021 08; 148(2).
Score: 0.017
-
Comparison of Parental Report of Influenza Vaccination to Documented Records in Children Hospitalized With Acute Respiratory Illness, 2015-2016. J Pediatric Infect Dis Soc. 2021 Apr 30; 10(4):389-397.
Score: 0.017
-
Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children: Multicenter Surveillance, United States, January-March 2020. J Pediatric Infect Dis Soc. 2020 Nov 10; 9(5):609-612.
Score: 0.016
-
Vaccine Effectiveness Against Pediatric Influenza Hospitalizations and Emergency Visits. Pediatrics. 2020 11; 146(5).
Score: 0.016
-
Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020 07; 146(1).
Score: 0.016
-
Evidence for Household Transmission of Rotavirus in the United States, 2011-2016. J Pediatric Infect Dis Soc. 2020 Apr 30; 9(2):181-187.
Score: 0.016
-
Association of Rotavirus Vaccination With Inpatient and Emergency Department Visits Among Children Seeking Care for Acute Gastroenteritis, 2010-2016. JAMA Netw Open. 2019 09 04; 2(9):e1912242.
Score: 0.015
-
Enterovirus D68-Associated Acute Respiratory Illness - New Vaccine Surveillance Network, United States, July-October, 2017 and 2018. MMWR Morb Mortal Wkly Rep. 2019 Mar 29; 68(12):277-280.
Score: 0.014
-
Factors Associated With Rotavirus Vaccine Coverage. Pediatrics. 2019 02; 143(2).
Score: 0.014
-
Rotavirus Strain Trends During the Postlicensure Vaccine Era: United States, 2008-2013. J Infect Dis. 2016 09 01; 214(5):732-8.
Score: 0.012
-
Epidemiologic Association Between FUT2 Secretor Status and Severe Rotavirus Gastroenteritis in Children in the United States. JAMA Pediatr. 2015 Nov; 169(11):1040-5.
Score: 0.011
-
Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013. Clin Infect Dis. 2015 Dec 15; 61(12):1792-9.
Score: 0.011
-
Innate Susceptibility to Norovirus Infections Influenced by FUT2 Genotype in a United States Pediatric Population. Clin Infect Dis. 2015 Jun 01; 60(11):1631-8.
Score: 0.011
-
Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis. 2013 Jul; 57(1):13-20.
Score: 0.009
-
Detection of rotavirus antigenemia in routinely obtained serum specimens to augment surveillance and vaccine effectiveness evaluations. Pediatr Infect Dis J. 2010 Sep; 29(9):836-9.
Score: 0.008
-
Use of an immunization information system to assess the effectiveness of pentavalent rotavirus vaccine in US children. Vaccine. 2010 Aug 31; 28(38):6314-7.
Score: 0.008
-
Cost-effectiveness analysis of a practice-based immunization education intervention. Ambul Pediatr. 2007 Mar-Apr; 7(2):167-75.
Score: 0.006